CA2963175A1 - Bispecific antibodies and methods of use in ophthalmology - Google Patents

Bispecific antibodies and methods of use in ophthalmology Download PDF

Info

Publication number
CA2963175A1
CA2963175A1 CA2963175A CA2963175A CA2963175A1 CA 2963175 A1 CA2963175 A1 CA 2963175A1 CA 2963175 A CA2963175 A CA 2963175A CA 2963175 A CA2963175 A CA 2963175A CA 2963175 A1 CA2963175 A1 CA 2963175A1
Authority
CA
Canada
Prior art keywords
amino acid
hvr
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2963175A
Other languages
English (en)
French (fr)
Inventor
Marc BEDOUCHA
Sebastian Breuer
Stefan DENGL
Christian Gassner
Guy Georges
Sabine Gruener
Guido Hartmann
Peter Michael HUELSMANN
Hubert Kettenberger
Joerg Moelleken
Michael MOLHOJ
Olaf Mundigl
Joerg Thomas Regula
Ralf Schumacher
Barbara Weiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2963175A1 publication Critical patent/CA2963175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2963175A 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology Abandoned CA2963175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192517.2 2014-11-10
EP14192517 2014-11-10
PCT/EP2015/075879 WO2016075037A1 (en) 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology

Publications (1)

Publication Number Publication Date
CA2963175A1 true CA2963175A1 (en) 2016-05-19

Family

ID=51868112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963175A Abandoned CA2963175A1 (en) 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology

Country Status (15)

Country Link
US (1) US10730938B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218399A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017537896A (cg-RX-API-DMAC7.html)
KR (1) KR20170080584A (cg-RX-API-DMAC7.html)
CN (1) CN107074941A (cg-RX-API-DMAC7.html)
AR (1) AR102592A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015345323A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017009764A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963175A1 (cg-RX-API-DMAC7.html)
IL (1) IL251128A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017005977A (cg-RX-API-DMAC7.html)
RU (1) RU2017120360A (cg-RX-API-DMAC7.html)
SG (1) SG11201703428SA (cg-RX-API-DMAC7.html)
TW (1) TW201632551A (cg-RX-API-DMAC7.html)
WO (1) WO2016075037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
SG11201703458UA (en) * 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US10836819B2 (en) 2016-08-23 2020-11-17 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
MY199149A (en) * 2018-12-21 2023-10-18 Hoffmann La Roche Antibody that binds to vegf and il-1beta and methods of use
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021198034A1 (en) * 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
EP4349861A4 (en) * 2021-06-04 2025-07-23 Innovent Biologics Suzhou Co Ltd BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND ITS USE
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025211874A1 (ko) * 2024-04-04 2025-10-09 주식회사 크로스포인트테라퓨틱스 인간 항체 fc 변이체 포함 이중항체 및 그 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2003208946A1 (en) 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2509136C (en) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
EP1587830B1 (en) 2003-01-28 2009-07-08 Academisch Ziekenhuis Leiden Peptide inhibitors of toxins derived from ll-37
US20050226863A1 (en) 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
CA2727171A1 (en) 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
EP2488201A4 (en) 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
CN102883748A (zh) * 2010-05-07 2013-01-16 爱克索马技术有限公司 治疗IL-1β相关状况的方法
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
JP6069312B2 (ja) 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
EP2867360B1 (en) * 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150060686A (ko) 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
CN104661678A (zh) 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
EP2917237A1 (en) * 2012-11-09 2015-09-16 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PE20160753A1 (es) 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
US11198726B2 (en) 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy

Also Published As

Publication number Publication date
RU2017120360A3 (cg-RX-API-DMAC7.html) 2019-10-18
US20170240629A1 (en) 2017-08-24
MX2017005977A (es) 2017-06-29
BR112017009764A2 (pt) 2018-02-20
CN107074941A (zh) 2017-08-18
TW201632551A (zh) 2016-09-16
AU2015345323A1 (en) 2017-04-06
WO2016075037A1 (en) 2016-05-19
SG11201703428SA (en) 2017-05-30
US10730938B2 (en) 2020-08-04
JP2017537896A (ja) 2017-12-21
RU2017120360A (ru) 2018-12-13
EP3218399A1 (en) 2017-09-20
IL251128A0 (en) 2017-04-30
KR20170080584A (ko) 2017-07-10
AR102592A1 (es) 2017-03-08

Similar Documents

Publication Publication Date Title
US10730938B2 (en) Bispecific antibodies and methods of use in ophthalmology
US10344085B2 (en) Anti-IL-1beta antibodies
US20230183349A1 (en) Anti-pd1 antibodies and methods of use
US10087246B2 (en) Anti-PDGF-B antibodies and methods of use
AU2016333511B2 (en) Humanized anti-human CD19 antibodies and methods of use
US11820816B2 (en) Anti-VEGF antibodies and methods of use
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology
HK1238257A1 (en) Anti-il-1beta antibodies and methods of use
HK1239711A1 (en) Anti-pdgf-b antibodies and methods of use
HK1239711B (zh) 抗-pdgf-b抗体和使用方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220127